| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DIRAS1 |
| Uniprot No | O95057 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-195aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMPEQSNDYRVVVFGAGGVGKSSLVLRFVKG TFRDTYIPTIEDTYRQVISCDKSVCTLQITDTTGSHQFPAMQRLSISKGH AFILVFSVTSKQSLEELGPIYKLIVQIKGSVEDIPVMLVGNKCDETQREV DTREAQAVAQEWKCAFMETSAKMNYNVKELFQELLTLETRRNMSLNIDGK RSGKQKRTDRVKGKC |
| 预测分子量 | 24 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DIRAS1重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**：*"DIRAS1 regulates autophagy and tumorigenesis through modulating mTORC2 signaling"*
**作者**：Zhang, Y., et al.
**摘要**：该研究通过表达重组DIRAS1蛋白，揭示其通过抑制mTORC2复合体的活性调控自噬过程，从而抑制肿瘤细胞的增殖和转移，为癌症治疗提供了潜在靶点。
---
2. **文献名称**：*"Recombinant DIRAS1 binds to 14-3-3 proteins and inhibits RAS-MAPK signaling in glioblastoma"*
**作者**：Wang, L., et al.
**摘要**：作者利用大肠杆菌系统表达并纯化DIRAS1重组蛋白，证明其通过与14-3-3蛋白相互作用，抑制RAS-MAPK信号通路，降低胶质母细胞瘤细胞的侵袭能力。
---
3. **文献名称**：*"Structural insights into the GTPase activity of DIRAS1 recombinant protein"*
**作者**：Kumar, S., et al.
**摘要**：本研究解析了DIRAS1重组蛋白的晶体结构，发现其GTPase结构域的独特构象变化，揭示了DIRAS1在GTP水解中的低活性特征，并探讨了其与经典RAS蛋白的功能差异。
---
**备注**：上述文献为示例性质，实际研究中建议通过PubMed或Web of Science以“DIRAS1 recombinant protein”为关键词检索最新论文。若需具体文献，可提供数据库访问权限以便获取真实引用信息。
DIRAS1 (DIRAS Family GTPase 1) is a member of the Ras superfamily of small GTPases, which are molecular switches regulating diverse cellular processes such as proliferation, differentiation, and apoptosis. Unlike oncogenic Ras proteins, DIRAS1 is classified as a tumor suppressor due to its role in inhibiting cell growth and promoting autophagy. It shares structural homology with other DIRAS family members, including a conserved GTP-binding domain and effector interaction motifs, but exhibits distinct tissue-specific expression patterns, with higher levels observed in the brain, heart, and reproductive organs.
Functionally, DIRAS1 cycles between an active GTP-bound state and an inactive GDP-bound state, interacting with downstream effectors to modulate signaling pathways like mTOR and MAPK. Studies suggest it induces cell cycle arrest and apoptosis under stress conditions, while also enhancing autophagic flux to maintain cellular homeostasis. Its dysregulation has been linked to cancers (e.g., ovarian, breast) and neurodegenerative disorders, where reduced DIRAS1 expression correlates with disease progression.
Recombinant DIRAS1 protein, typically produced in *E. coli* or mammalian expression systems, retains GTPase activity and structural integrity, enabling *in vitro* studies to dissect its mechanistic roles. This tool has been pivotal in identifying binding partners, validating enzymatic kinetics, and screening therapeutic compounds aiming to restore DIRAS1 function in pathologies. Its application extends to antibody development, structural biology, and preclinical models exploring DIRAS1-based therapies. Despite progress, its tissue-specific regulation and crosstalk with other GTPases remain active research areas.
×
